Onasemnogene abeparvovec Drug Due Diligence Report 2026

This Onasemnogene abeparvovec Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Onasemnogene abeparvovec can convert its AAV based gene therapy profile and SMN1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Onasemnogene abeparvovec (query alias: Onasemnogene abeparvovec)
Modality / target	AAV based gene therapy; SMN1; SMN1 gene stimulants
Highest global status	Approved
Originator	Novartis Gene Therapies, Inc., Novartis Pharma AG
Active developers	Beijing Novartis Pharma Co. Ltd., Novartis Europharm Ltd., Novartis Pharma AG

The MCP disease footprint includes Spinal Muscular Atrophy, Muscular Atrophy, Spinal, Type II. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07448610	Phase 4	Not yet recruiting	36	Change from baseline in HFMSE for independently ambulatory participants
NCT06019637	Not Applicable	Recruiting	50	Incidence and severity of treatment-emergent SAEs
IRCT20221024056284N1	Not Applicable	Complete	50	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Onasemnogene Abeparvovec in Patients With <scp>SMA</scp> : Interim Results of the <scp>RESTORE</scp> Registry in Japan

Not Applicable; n=80; evaluation: Positive. Reported fields: AE(related to OA) = 98.8 %

Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study

Phase 1; n=13; evaluation: Positive. Reported fields: AESI = 31.0 %

Long-Term Real-World Outcomes Following Onasemnogene Abeparvovec Monotherapy for Patients with SMA: Updated Findings from the RESTORE Registry

Not Applicable; n=251; evaluation: Positive. Reported fields: AE = 109.0 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Onasemnogene abeparvovec addresses Spinal Muscular Atrophy, Muscular Atrophy, Spinal, Type II. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—AAV based gene therapy—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-12-22	Riding on rosy estimates of Zolgensma sales, RegenxBio sells part of its royalty for $200M	Approved	US$200.0M stated total
2014-04-01	REGENX Biosciences and AveXis Enter into Exclusive Agreement for Development of Treatments for SMA	Discovery	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO